Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate.

ABSTRACT:

Background

American cutaneous leishmaniasis (ACL) is a complicated disease producing about 67.000 new cases per year. The severity of the disease depends on the parasite species; however in the vast majority of cases species confirmation is not feasible. WHO suggestion for ACL produced by Leishmania braziliensis, as first line treatment, are pentavalent antimonial derivatives (Glucantime or Sodium Stibogluconate) under systemic administration. According to different authors, pentavalent antimonial derivatives as treatment for ACL show a healing rate of about 75% and reasons for treatment failure are not well known.

Methods

In order to characterise the clinical and parasitological features of patients with ACL that did not respond to Glucantime, a cross-sectional observationa

SUBMITTER: Perez-Franco JE 

PROVIDER: S-EPMC4887049 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature